Back to News
Market Impact: 0.4
Agomab Reports 97% Clinical Remission With Ontunisertib At Week 48
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Agomab Therapeutics reported positive topline results from the 48-week open-label extension of its Phase 2a STENOVA trial of ontunisertib in fibrostenosing Crohn's disease. The clinical update supports continued development of the drug candidate and is a positive catalyst for the company, though the article provides no efficacy or safety figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
AGMB0.78
More News
- Broadcom to lend Anthropic up to $42 billion to lease its chips, filing says
- Nike Warns Sales Slump Will Worsen This Fiscal Year
- $8.2B acquisition validates AI-picked chip stock: +20% since June
- Nuveen CEO on Schroders Deal, Plans for Combined Company
- New Mexico wants Meta to pay up to $40 billion in penalties after data privacy trial
- Markets slip on dollar pressure, but this IT stock is up 10% today